The UK regulator has said eligible patients with prostate cancer will get early access to a radioligand therapy developed by Novartis' Advanced Accelerator Applications (AAA) subsidiary wh
Novartis has been steadily investing in radiopharmaceuticals over the last few years, and one of those deals has just paid off with an FDA approval for Pluvicto, the first targeted radiolig
